Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

HIV drug fails to prove COVID-19 prevention in abandoned trial

NCT ID NCT04405271

Prevention Sponsor: Hospital Italiano de Buenos Aires Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tested whether a daily pill used for HIV (TAF/FTC) could prevent COVID-19 in healthcare workers at high risk of exposure. Over 1,300 workers were randomly assigned to get the drug or a placebo for 12 weeks. The trial was stopped early, so it's unclear if the drug had any real benefit.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Emtricitabine/Tenofovir Alafenamide (FTC/TAF) oral tablet
What this could lead to
If it had worked, this could have pointed toward a new way to prevent COVID-19 in high-risk workers using an existing HIV drug.
What could go wrong
The trial was terminated early, so we don't have clear evidence it works. Also, this drug is normally for HIV, and its effectiveness against COVID-19 was uncertain from the start.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

1,378 people

The number who actually took part.

Started

Jul 2020

Finished

Nov 2020

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Healthcare workers voluntarily deciding to participate in the study 2. Understanding the study purpose 3. Having between 18 and 70 years old 4. Having a high transmission risk for Covid-19. Physicians, nurses, lab technicians, physical therapists, or cleaning personnel working at COVID-19 areas, hospital emergency areas, or Intensive care units from healthcare institutions with the direct assistance of patients with Covid-19. 5. Not having a prior diagnosis of SARS-CoV-2 infection (COVID-19) 6. Having a negative IgM/IgG antibodies test for SARS-CoV-2 (COVID-19) prior to study entry 7. Negative pregnancy test for childbearing age women within 7 days prior to study entry. 8. Childbearing age males and females should comply with the use of a proven contraceptive method (double barrier methods, oral contraceptives or contraceptive hormone implants) during the course of the study and at least one month after study completion. Exclusion Criteria: 1. Having symptoms compatible with COVID-19 2. Diagnosed HIV infection 3. Current use of Pre-exposure prophylaxis for HIV 4. Diagnosed Hepatitis B infection. 5. Diagnosed renal insufficiency and or current hemodialysis need 6. Diagnosed osteoporosis under pharmacological treatment. 7. Weight \< 40kg 8. Current immunosuppressive or serious hematological condition 9. Prior use of pre-exposure prophylaxis for SARS-CoV-2 10. Current pregnancy or pregnancy plan within the study course. 11. Current breastfeeding 12. Known hypersensitivity to any of the study medication components.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

severe acute respiratory syndrome COVID-19 prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID-19 Healthcare workers SARS-CoV-2

Contacts and locations

Locations

  • Sociedad Argentina de Infectología, A. J. Carranza 974

    Buenos Aires, Buenos Aires F.D., C1085, Argentina

More trials for these conditions

Other studies related to the condition(s) this trial covers.